Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
September 11, 2023 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx, Inc. Reports Employment Inducement Grants
September 07, 2023 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
August 02, 2023 07:00 ET
|
Ardelyx, Inc.
Continued successful launch of IBSRELA, with Q2 net sales revenue of $18.3 million; Company currently expects 2023 full year IBSRELA net sales revenue to be $72 to $77 million XPHOZAH expected to...
Ardelyx, Inc. Reports Employment Inducement Grants
July 27, 2023 16:05 ET
|
Ardelyx, Inc.
WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
July 26, 2023 07:55 ET
|
Ardelyx, Inc.
WALTHAM, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
July 20, 2023 16:05 ET
|
Ardelyx, Inc.
WALTHAM, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
July 13, 2023 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx, Inc. Reports Employment Inducement Grants
June 29, 2023 16:09 ET
|
Ardelyx, Inc.
WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
June 05, 2023 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...